Neuromodulation for a Novel OCD Biomarker and Treatment
RecruitingNCT05994053Phase: NAStarted 2024-07-01
Summary
Although multiple treatments for OCD exist, slow symptom decrease, high remission, and significant side effects for some OCD patients limit their efficacy. More research into the precise neural mechan
Eligibility
Sex
ALL
Min Age
18 Years
Max Age
None
Locations
Boston University Center for Anxiety and Related Disorders (Boston, Massachusetts, United States
View full study details on ClinicalTrials.gov
clinicaltrials.gov/study/NCT05994053